Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$177M |
Are Monte Rosa Therapeutics Insiders Buying or Selling?
Monte Rosa Therapeutics (GLUE) has had 3 insider transactions in the past 90 days, all sells. The most recent was Matthew Bowen, who sold 13 shares at $10.56 on October 5, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the GLUE AI Score. For government officials trading this stock, see GLUE congressional trading.
Who’s Trading Monte Rosa Therapeutics Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Versant Venture Capital VI, L.P. | Sold $1.5M | 3 | Oct 29, 2024 |
| Filip Janku | Sold $1.2M | 5 | Jun 30, 2026 |
| Markus Warmuth | Sold $950,000 | 10 | Jul 16, 2026 |
| Edmund Dunn | Sold $490,000 | 5 | Mar 4, 2026 |
| Sharon Townson | Sold $370,000 | 5 | Jul 6, 2026 |
| Jennifer Champoux | Sold $270,000 | 5 | Jul 15, 2026 |
Recent Monte Rosa Therapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Matthew Bowen | Oct 5, 2026 | Sell | 13 | $10.56 | $140 |
| Markus Warmuth | Jul 16, 2026 | Sell | 9,500 | $23.18 | $220,000 |
| Jennifer Champoux | Jul 15, 2026 | Sell | 4,351 | $23.38 | $100,000 |
| Sharon Townson | Jul 6, 2026 | Sell | 5,600 | $23.25 | $130,000 |
| Sharon Townson | Jul 6, 2026 | Sell | 400 | $24.13 | $9,700 |
| Filip Janku | Jun 30, 2026 | Sell | 5,407 | $24.5 | $130,000 |
| Filip Janku | Jun 24, 2026 | Sell | 30,000 | $21.42 | $640,000 |
| Filip Janku | Jun 23, 2026 | Sell | 11,845 | $20.22 | $240,000 |
| Sharon Townson | Jun 23, 2026 | Sell | 3,000 | $20 | $60,000 |
| Jennifer Champoux | Jun 23, 2026 | Sell | 2,175 | $20 | $44,000 |
| Markus Warmuth | Jun 1, 2026 | Sell | 4,998 | $19.41 | $97,000 |
| Markus Warmuth | Jun 1, 2026 | Sell | 468 | $19.73 | $9,200 |
| Sharon Townson | May 29, 2026 | Sell | 6,000 | $19.87 | $120,000 |
| Jennifer Champoux | May 27, 2026 | Sell | 2,175 | $20 | $44,000 |
| Jennifer Champoux | May 22, 2026 | Sell | 2,176 | $19 | $41,000 |
| Anthony Manning | May 21, 2026 | Sell | 10,000 | $18.01 | $180,000 |
| Markus Warmuth | May 1, 2026 | Sell | 5,467 | $18.92 | $100,000 |
| Markus Warmuth | Apr 14, 2026 | Sell | 8,000 | $17.64 | $140,000 |
| Philip Nickson | Apr 9, 2026 | Sell | 5,845 | $17.69 | $100,000 |
| Edmund Dunn | Mar 4, 2026 | Sell | 139 | $17.96 | $2,500 |
| Markus Warmuth | Mar 2, 2026 | Sell | 5,466 | $17.92 | $98,000 |
| Edmund Dunn | Mar 2, 2026 | Sell | 536 | $17.5 | $9,400 |
| Edmund Dunn | Feb 27, 2026 | Sell | 25,164 | $18.1 | $460,000 |
| Filip Janku | Feb 23, 2026 | Sell | 9,189 | $19.5 | $180,000 |
| Markus Warmuth | Jan 7, 2026 | Sell | 3,707 | $23.24 | $86,000 |
| Markus Warmuth | Jan 7, 2026 | Sell | 1,450 | $23.88 | $35,000 |
| Markus Warmuth | Jan 7, 2026 | Sell | 309 | $24.57 | $7,600 |
| Markus Warmuth | Jan 5, 2026 | Sell | 10,135 | $15.17 | $150,000 |
| Philip Nickson | Jan 5, 2026 | Sell | 3,155 | $15.17 | $48,000 |
| Jennifer Champoux | Jan 5, 2026 | Sell | 2,629 | $15.17 | $40,000 |
| Edmund Dunn | Jan 5, 2026 | Sell | 1,039 | $15.17 | $16,000 |
| Filip Janku | Jan 5, 2026 | Sell | 3,155 | $15.17 | $48,000 |
| Sharon Townson | Jan 5, 2026 | Sell | 3,155 | $15.17 | $48,000 |
| Edmund Dunn | Jun 3, 2025 | Sell | 2,062 | $4.45 | $9,200 |
| Chandra Leo | Mar 24, 2025 | Buy | 10,000 | $5.84 | $58,000 |
| Versant Venture Capital VI, L.P. | Oct 29, 2024 | Sell | 52,305 | $9.08 | $480,000 |
| Versant Venture Capital VI, L.P. | Oct 29, 2024 | Sell | 15,600 | $9.41 | $150,000 |
| Versant Venture Capital VI, L.P. | Oct 28, 2024 | Sell | 89,990 | $9.66 | $870,000 |
Frequently Asked Questions: Monte Rosa Therapeutics Insider Trading
In the past 90 days, Monte Rosa Therapeutics insiders have made 0 buys and 3 sells. The net selling may indicate insiders are taking profits or reducing exposure.
The most recent sale was by Matthew Bowen who sold 13 shares on October 5, 2026. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Leo Chandra P. has bought the most GLUE stock in the last 2 years, with a total value of $58,000.
Versant Venture Capital VI, L.P. has sold the most GLUE stock in the last 2 years, with a total value of $1.5M.
The total value of insider transactions for Monte Rosa Therapeutics in the last 2 years is negative, amounting to -$5.1M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
